Neratinib, a TKI directed against HER1/HER2/HER4 has recently been approved by the Food and Drug Administration (FDA) for adjuvant treatment of patients with early stage HER2-overexpressed/amplified breast cancer. This evidence concerns the gene ERBB4 and breast cancer.